NCT06411301View on ClinicalTrials.gov

A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Multiple Myeloma, RefractoryMultiple Myeloma in RelapseMultiple Myeloma Progression
Interventions
DRUG

225Ac-DOTATATE

Two intravenous infusions every 6 weeks (Q6W)

Trial Locations (1)

1070

Jules Bordet Institute, Brussels

Sponsors
All Listed Sponsors
collaborator

RayzeBio, Inc.

INDUSTRY

lead

Jules Bordet Institute

OTHER